UFP TECHNOLOGIES INC (UFPT): Results of Operations and Financial Condition
UFP TECHNOLOGIES INC (UFPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 UFP Technologies Announces Record Q2 Results Newburyport, Mass., August 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and ot
How this was made
The 30-second read
Why it matters
The disclosure is a primary earnings update: sales growth, margin expansion, and higher GAAP and adjusted EPS, alongside a stated operational investment headwind that may affect near-term profitability.
Market read
Traders can reassess UFPT’s growth and margin trajectory immediately based on the reported Q2 and first-half numbers and the stated near-term margin pressure from capacity investments.
What to watch
SG&A rose faster than sales (as a percent of sales), and the narrative suggests margin pressure in U.S. operations could cap upside even with strong top-line growth.
UFP Technologies Announces Record Q2 Results
Record quarterly sales, net income and EPS were accompanied by double-digit sales, operating-income and adjusted EBITDA growth, while higher SG&A and Dominican Republic investments created mix and margin pressure within U.S. operations.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net salesGAAP | $174.0 million | – | 15.1% |
| Organic sales growthnon-GAAP | 12.4% | – | – |
| Cost of salesGAAP | $ 123,046 (in thousands) | – | – |
| Gross profitGAAP | $ 50,918 (in thousands) | – | – |
| Gross marginGAAP | 29.3% | – | – |
| Selling, general & administrative expensesGAAP | $22.8 million | – | 21.8% |
| SG&A as a percentage of salesGAAP | 13.1% | – | – |
| Adjusted SG&A as a percentage of salesnon-GAAP | 11.7% | – | – |
| Acquisition costsGAAP | 72 (in thousands) | – | – |
| Change in fair value of contingent considerationGAAP | — | – | – |
| Gain on disposal of property, plant & equipmentGAAP | (6) (in thousands) | – | – |
| Operating incomeGAAP | $28.1 million | – | 15.5% |
| Adjusted operating incomenon-GAAP | $30.6 million | – | 12.3% |
| Interest expense, netGAAP | 1,711 (in thousands) | – | – |
| Other (income) expenseGAAP | (40) (in thousands) | – | – |
| Income before income tax expenseGAAP | 26,428 (in thousands) | – | – |
| Income tax expenseGAAP | 5,577 (in thousands) | – | – |
| Net incomeGAAP | $20.9 million | – | 21.4% |
| Adjusted net incomenon-GAAP | $22.7 million | – | 17.2% |
| Net income per shareGAAP | $2.69 | – | – |
| Net income per diluted shareGAAP | $2.68 | – | – |
| Adjusted diluted EPSnon-GAAP | $2.92 | – | – |
| Weighted average common shares outstandingGAAP | 7,740 (in thousands) | – | – |
| Weighted average diluted common shares outstandingGAAP | 7,788 (in thousands) | – | – |
| Adjusted EBITDAnon-GAAP | $36.4 million | – | 14.3% |
| Six-month net salesGAAP | $328.2 million | – | 9.6% |
| Six-month organic sales growthnon-GAAP | 6.8% | – | – |
| Six-month gross profitGAAP | 95,280 (in thousands) | – | – |
| Six-month gross marginGAAP | 29.0% | – | – |
| Six-month selling, general & administrative expensesGAAP | $43.8 million | – | 17.0% |
| Six-month SG&A as a percentage of salesGAAP | 13.3% | – | – |
| Six-month adjusted SG&A as a percentage of salesnon-GAAP | 11.8% | – | – |
| Six-month operating incomeGAAP | $51.5 million | – | 8.5% |
| Six-month adjusted operating incomenon-GAAP | $56.5 million | – | 6.4% |
| Six-month net incomeGAAP | $38.3 million | – | 11.6% |
| Six-month adjusted net incomenon-GAAP | $42.1 million | – | 8.9% |
| Six-month net income per shareGAAP | $4.96 | – | – |
| Six-month net income per diluted shareGAAP | $4.92 | – | – |
| Six-month adjusted EPSnon-GAAP | $5.39 | – | – |
| Six-month adjusted EBITDAnon-GAAP | $67.3 million | – | 8.5% |
What drove it
- Top five customers grew 14.7% during the quarter.
- The balance of the MedTech business grew 19.7% during the quarter.
- Non-medical business was flat during the quarter.
- Management attributed results to contributions across the UFP platform and the strength and diversity of its MedTech business.
- The company continues to invest in Dominican Republic operations to support customer-driven growth initiatives, expand capacity and enhance its cost structure over time.
Concerns
- SG&A increased 21.8% to $22.8 million, faster than 15.1% sales growth.
- GAAP SG&A as a percentage of sales increased to 13.1% from 12.4%, while adjusted SG&A as a percentage of sales increased to 11.7% from 10.8%.
- Management said full realization of benefits from Dominican Republic investments is taking longer than anticipated.
- Management said Dominican Republic investments are creating near-term mix and margin pressure within U.S. operations.
- Non-medical business was flat.
What to watch
- Progress in realizing operational and cost-structure benefits from Dominican Republic investments.
- Whether management can reduce near-term mix and margin pressure within U.S. operations.
- Growth from existing customers, new program launches and the four large programs cited in the forward-looking statements.
- Sales trends among the top five customers, the remaining MedTech business and non-medical business.
- Execution of disciplined acquisitions and continued leadership-team expansion.
Balance sheet and cash flow
- Cash and cash equivalents were $ 9,045 (in thousands) at June 30, 2026, compared with $ 20,301 (in thousands) at December 31, 2025.
- Receivables, net were 113,247 (in thousands) at June 30, 2026, compared with 82,914 (in thousands) at December 31, 2025.
- Inventories were 100,090 (in thousands) at June 30, 2026, compared with 86,856 (in thousands) at December 31, 2025.
- Net property, plant, and equipment were 76,916 (in thousands) at June 30, 2026, compared with 79,109 (in thousands) at December 31, 2025.
- Current installments, net of long-term debt were 12,500 (in thousands) at June 30, 2026 and 12,500 (in thousands) at December 31, 2025.
- Long-term debt, excluding current installments, was 104,805 (in thousands) at June 30, 2026, compared with 122,955 (in thousands) at December 31, 2025.
- Total assets were $ 681,909 (in thousands) at June 30, 2026, compared with $ 655,077 (in thousands) at December 31, 2025.
- Total liabilities were 219,484 (in thousands) at June 30, 2026, compared with 231,200 (in thousands) at December 31, 2025.
- Total equity was 462,425 (in thousands) at June 30, 2026, compared with 423,877 (in thousands) at December 31, 2025.
Analysis
UFP Technologies reported record quarterly net sales, net income and EPS for the second quarter ended June 30, 2026. Net sales rose 15.1% to $174.0 million, with 12.4% organic sales growth. GAAP operating income increased 15.5% to $28.1 million, net income increased 21.4% to $20.9 million, and adjusted EBITDA increased 14.3% to $36.4 million. For the six-month period, sales increased 9.6% to $328.2 million and adjusted EBITDA increased 8.5% to $67.3 million.
Demand was concentrated in the medical platform. The top five customers grew 14.7%, while the balance of the MedTech business grew 19.7%; non-medical business was flat. Management cited broad contributions across the platform and the strength and diversity of the MedTech business. It also identified opportunities in existing-customer growth, new program launches and four large programs referenced in its forward-looking statements.
Profitability improved at the gross-profit level, with second-quarter gross margin increasing to 29.3% from 28.8%, and six-month gross margin increasing to 29.0% from 28.6%. Expense leverage was less favorable: quarterly SG&A rose 21.8% to $22.8 million and reached 13.1% of sales, compared with 12.4% a year earlier. Adjusted SG&A as a percentage of sales rose to 11.7% from 10.8%. Management attributed near-term mix and margin pressure within U.S. operations to investments in the Dominican Republic and said the full realization of associated benefits is taking longer than anticipated.
The balance sheet showed $ 9,045 (in thousands) of cash and cash equivalents at June 30, 2026, against long-term debt, excluding current installments, of 104,805 (in thousands). Receivables and inventories were 113,247 (in thousands) and 100,090 (in thousands), respectively. The release did not report operating cash flow, free cash flow, repurchases or dividends.
Management did not provide quantitative forward guidance. Its stated priorities are to support customer-driven growth initiatives, expand Dominican Republic capacity, enhance cost structure, pursue disciplined acquisitions, and add organizational capacity through leadership investments. The key operating issue is whether the company can convert those investments into the anticipated operational benefits while sustaining MedTech-led growth and containing U.S. mix and margin pressure.
Management, verbatim
Our second quarter and first-half results reflect solid execution across the platform and continued progress toward our long-term growth strategy.
Mitch Rock, President and Chief Executive Officer
During the quarter, our top five customers grew 14.7%, the balance of our MedTech business grew 19.7%, and our non-medical business was flat.
Mitch Rock, President and Chief Executive Officer
Looking ahead, we continue to see meaningful opportunities to grow with existing customers, support new program launches, pursue disciplined acquisitions, and invest in our people and capabilities.
Mitch Rock, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quantitative forward revenue guidance
- Quantitative forward gross-margin guidance
- Quantitative forward operating-expense guidance
- Quantitative forward tax-rate guidance
- Prior outlook for comparison with actual results
- Prior-quarter comparisons for reported metrics
- Reportable-segment revenue
- Operating cash flow
- Free cash flow
- Share repurchases
- Dividends
- Cash-flow statement
- Adjusted EPS prior-year figure for the six-month period
- Adjusted net income prior-year unit for the six-month period beyond the printed value of $38.6
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
UFP Technologies (UFPT) filed an 8-K with Exhibit 99.1 reporting Q2 and six-month ended June 30, 2026 financial results and management commentary.
Ticker impact
UFP Technologies reported record Q2 results with net income $20.9M (+21.4%) and net sales $174.0M (+15.1%).
Likely supportive for near-term sentiment given margin and earnings growth, with some offset from the stated near-term margin pressure.
The filing provides concrete GAAP and adjusted EPS, sales, gross margin, and operating income changes, plus a specific forward-looking operational headwind tied to capacity investment timing.
Market effects
Signals continued demand and pricing/mix strength in MedTech manufacturing and sterile packaging, with capacity investment translating into early benefits.
Dominican Republic capacity investment is highlighted as a driver of near-term U.S. mix and margin pressure.
Limited direct global macro linkage; primarily company-specific execution in medical device supply chains.
Counterpoint
Despite record results, the company explicitly warns that Dominican Republic investment benefits are taking longer, implying earnings quality could be pressured in the near term.
Key entities
- companyUFP Technologies, Inc.
Contract development and manufacturing organization focused on medical devices and sterile packaging; reported record Q2 and first-half results.
- executiveMitch Rock
President and CEO who discussed performance drivers and the timing of benefits from Dominican Republic investments.
